R&D Organization
With the aim of identifying solutions and bringing our pharmaceuticals to patients around the world as quickly as possible, Kyowa Hakko Kirin has assembled a comprehensive organization of research and development facilities.
While pursuing discovery research targeting new drug development, this center aims at creating antibody development candidates.
From the discovery of pharmaceutical candidates to guiding them through the clinical testing stages, this center is the core of Kyowa Hakko Kirin's pharmaceutical research and development activities.
Kyowa Hakko Kirin is also developing new production technologies for antibody pharmaceuticals and other drugs resulting from our biotechnology R&D and reinforcing capabilities to produce pharmaceuticals for clinical research.
Overseas R&D activities
BioWa, Inc. / U.S.A. - BioWa is a (exclusive world-wide) licensor of Enhanced Antibody Activity Technology (POTELLIGENT® and COMPLEGENT®).
Hematech, Inc. / U.S.A.- Research and development continues into the technology base for the production of polyclonal antibody medicines.
- Kyowa Hakko Kirin California, Inc. / U.S.A.
- With the cooperation of U.S.A-based medical research and the La Jolla Institute for Allergy & Immunology, progress is being made in drug discovery research and development in the USA.
- Kyowa Hakko Kirin Pharma, Inc. / U.S.A.
- Clinical development and research is ongoing in the USA.
- Kyowa Hakko Kirin UK Ltd. / U.K.
- Clinical development and research is ongoing in the EU.
